Intellia Therapeutics (NTLA) Misses Q2 EPS by 38c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
August 5, 2021 7:30 AM EDTEstablished proof of concept for the Companys modular in vivo delivery platform with first-ever clinical data from systemically administered CRISPR genome editing candidate in humansInterim Phase 1 data from first two cohorts show NTLA-2001 was well-tolerated and achieved deep TTR reduction, with a maximum 96% serum TTR reduction by day 28, demonstrating potential as single-dose treatment for transthyretin (ATTR) amyloidosis; plan to report additional data from ongoing study this year Plans to initiate first-in-human studies for both NTLA-2002 for hereditary angioedema (HAE) and NTLA-5001 for acute myeloid leukemia (AML) this yearLaunched CAR... More
